The reporting methods of noninferiority randomized clinical trials are often inconsistent, with many publications omitting ...

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

Older adults who developed incident HF showed acute declines in cognition, memory and executive function, followed by a steep ...

The burnout contagion continues to rage on, with no end in sight.Although we may see glimpses of positive reforms proposed to ...

At this year’s AIMed25 conference, attendees will learn more about the future of AI in health care from industry leaders, ...

Thousands of health care providers will attend this year’s Osteopathic Medical Education Conference, or OMED, taking place in ...

More than 8% of cancer survivors are likely using cannabis, but more than half of them may be using it recreationally.A study ...

State legislatures have become the front lines in the battle for affordable medications and improved access to rheumatology ...

In these videos, Douglas H. Jones, MD, the medical director and CEO of Global Allergy Immune Network, discusses the latest developments in the treatment and of hereditary angioedema.

In these videos, Douglas H. Jones, MD, the medical director and CEO of Global Allergy Immune Network, discusses the latest developments in the treatment and of hereditary angioedema.

In these videos, Douglas H. Jones, MD, the medical director and CEO of Global Allergy Immune Network, discusses the latest developments in the treatment and of hereditary angioedema.

In these videos, Douglas H. Jones, MD, the medical director and CEO of Global Allergy Immune Network, discusses the latest developments in the treatment and of hereditary angioedema.